

## AMENDMENTS TO THE CLAIMS

Claim 1 (currently amended): A method of inhibiting Fyn/Lck fatty acylation and protein palmitoylation in a cell in an individual ~~in need of such treatment~~ comprising ~~the step of~~:

administering to said individual a pharmacologically effective dose of 2-bromopalmitate.

Claim 2 (currently amended): The method of claim 1, wherein said 2-bromopalmitate is administered in a dose of ~~from~~ about 0.1 mg/kg to about 100 mg/kg of total body weight of said individual.

Claim 3 (currently amended): The method of claim 1, wherein said 2-bromopalmitate inhibits protein palmitoylation within the N-terminally palmitoylated N-terminus of the proteins.

Claim 4 (currently amended): The method of claim 1, wherein said 2-bromopalmitate further inhibits myristoylation of proteins.

Claim 5 (currently amended): The method of claim 1, wherein inhibiting Fyn/Lck fatty acylation further ~~said 2-bromopalmitate~~ inhibits T cell signaling events.

Claim 6 (currently amended): The method of claim 1, where said individual has ~~[[a]]~~ an autoimmune disease.

Claim 7 (currently amended): The method of claim [[1]] 6, where said autoimmune disease is ~~selected from the group consisting of~~ rheumatoid arthritis, Crohn's disease, diabetes, multiple sclerosis ~~and~~ or systemic lupus erythematosus.

Claim 8 (currently amended): A method of ~~treating~~ inhibiting T-cell receptor mediated signaling events in an individual having ~~a pathophysiological state~~ an autoimmune disease comprising ~~the step of:~~

administering to said individual a pharmacologically effective dose of 2-bromopalmitate; wherein 2-bromopalmitate inhibits Fyn/Lck fatty acylation in the T-cells thereby inhibiting T-cell receptor mediated signaling events in the individual.

Claim 9 (currently amended): The method of claim 8, where said 2-bromopalmitate is administered in a dose of ~~from~~ about 0.1 to about 100 mg/kg of total body weight of said individual.

Claim 10 -14 (canceled).

Claim 15 (currently amended): The method of claim [[14]] 8, wherein said autoimmune disease is ~~selected from the group consisting of~~ rheumatoid arthritis, diabetes, Crohn's disease, multiple sclerosis ~~and~~ or systemic lupus erythematosus.

Claim 16 (canceled).